The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells

Abstract 

The “allogeneic effect” refers to the induction of host B cell antibody synthesis or host T cell cytotoxicity, including tumoricidal activity, by an infusion of allogeneic lymphocytes. We show that treatment of mice with cyclophosphamide (Cy) followed by CD8⁺ T cell-depleted allogeneic donor lymphocyte infusion (Cy + CD8⁻ DLI) induces regression of established tumors with minimal toxicity in models of both hematologic and solid cancers, even though the donor cells are eventually rejected by the host immune system. The optimal antitumor effect of Cy + CD8⁻ DLI required the presence of donor CD4⁺ T cells, host CD8⁺ T cells, and alloantigen expression by normal host but not tumor tissue. The results support a model in which a donor CD4⁺ T cell-mediated graft-versus-host (GVH) reaction effectively awakens antitumor immunity among Cy-resistant host CD8⁺ T cells. These events provide the cellular mechanism of the “allogeneic effect” in antitumor immunity. Cy + CD8⁻ DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers.

Key Words: Allogeneic, Graft-versus-host disease, Adoptive immunotherapy, Cyclophosphamide, Lymphocyte subsets, graft-versus-tumor effects